Visão geral da empresa
A biopharmaceutical firm, Phathom Pharmaceuticals, Inc. is dedicated to the development and commercialization of therapeutic solutions specifically targeting gastrointestinal diseases within the United States market. The company operates within the Healthcare sector and the Biotechnology industry, positioning itself as a specialized player focused on advancing clinical solutions for specific patient populations. Phathom currently maintains a market capitalization of $833.69M and reported trailing twelve-month revenues of $175.11M, while employing a workforce of 371 individuals. The combination of a market cap in the high hundreds of millions and annual revenues exceeding $175 million indicates that the company has achieved a significant scale in its niche, moving beyond early-stage startup dynamics to a stage where commercialization of assets like VOQUEZNA is driving substantial top-line activity. This financial footprint suggests a mature biotechnology asset capable of supporting large-scale clinical trial programs and commercial infrastructure, despite the inherent risks associated with the biotechnology industry.
Saúde financeira
The company generated revenues of $175.11M over the trailing twelve months, yet recorded a net income loss of $221,247,008 and an EBITDA loss of $159,352,992, highlighting a substantial disconnect between top-line sales and bottom-line profitability. The significant gap between the $175.11M in revenue and the $221.2M net loss reveals a cost structure where operating expenses, likely driven by research, development, and commercialization efforts, far exceed current revenue streams. Free cash flow stood at $-107,858,128, indicating that the company is burning cash to fund its operations and pipeline development, which limits immediate financial flexibility but is typical for entities in the growth phase of the biotechnology lifecycle. Gross margin is reported at 87.1%, demonstrating high efficiency in the cost of goods sold relative to sales, while the operating margin sits at -10.3% and the profit margin is -126.3%, illustrating that high fixed costs and development expenditures are suppressing overall profitability. Cash on hand totals $129.97M, which is significantly lower than the total debt load of $589.17M, creating a leveraged balance sheet profile where liquidity is constrained by outstanding obligations. The current ratio of 1.73 suggests that the company possesses sufficient short-term assets to cover its current liabilities, providing a buffer against immediate liquidity pressures despite the negative cash flow. Return on Equity is listed as N/A, while Return on Assets is -31.4%, indicating that management is currently deploying capital to generate negative returns on the asset base as the company invests heavily in its growth trajectory.
Avaliação de valorização
The trailing twelve-month P/E ratio is N/A due to the negative earnings, whereas the forward P/E is 6.85, implying that the market anticipates a significant turnaround in profitability or a substantial reduction in costs to achieve positive earnings in the near future. The price-to-book ratio stands at -1.72, a negative figure that indicates the market is not valuing the company based on tangible book value, often seen in biotechnology firms where intangible assets like intellectual property and clinical data are more critical than physical assets. The price-to-sales ratio is 4.76, and the EV/EBITDA is -8.11, suggesting that valuation is primarily driven by revenue generation potential and future growth prospects rather than current earnings multiples or cash flow generation. The stock has traded between a 52-week low of $2.21 and a 52-week high of $18.31, meaning the current price sits at a specific point within a wide volatility range that reflects the high uncertainty inherent in the sector. The beta value is 0.56, indicating that the stock's price volatility is historically less sensitive to movements in the broader market compared to a standard equity with a beta of 1.0.
Growth & Income
Revenue growth year-over-year has accelerated to 94.1%, while earnings growth is N/A due to the company's continued net losses, which implies that top-line expansion is currently outpacing any potential for earnings improvement as the business scales. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the organization reinvests all available resources back into its research, development, and commercialization efforts rather than distributing income to shareholders. This reinvestment strategy is necessary to support the high growth rate observed in revenues, particularly as the company pushes VOQUEZNA through Phase III clinical trials and expands its commercial footprint. The overall growth and income profile is characterized by aggressive revenue expansion coupled with a complete absence of current income generation, reflecting a classic biotechnology company profile focused on long-term asset appreciation rather than short-term cash distribution.